Friday , June 18 2021

A new pencut allergy medicine is a promise to children

In the US where pancreatic allergies are present, more than one lakh children are becoming the first drug for the first stomach.

In one phase three trials, the results were published New England Journal of Medicine, Endangered medicine AR101 Serious groundnut allergies helped some chair kernels which lack certain side effects. Before taking any medication, none of these children could have more than one tenth of the kernel.

The AR101, built by Aimmune Therappeutics (designed and funded by the company), aims to determine the tolerance over time, provides daily protein, regulated proteins aimed at minimizing the risk of dangerous stimulus exhibition. Tolerance-building is a good strategy for blocking new allergens and controlling existing ones. But this is not a drug right now.

AR101 still needs recognition for Food and Drug Administration (FDA). However, the new trial results are encouraging, especially because panoramic allergies are more common, and 2.5% of children are affected.

500 children between the age group of 4 to 17 years and 50 adolescents studied. Data was collected in 10 countries in North America and Europe. Participants were arranged to receive the increasingly growing DOS, AR101 or a Playboy; They both ate the food as rows of food. People taking active medications every 20 weeks gradually increase the daily dose. Once this dose of 300 mg per day, this measure retained for 24 weeks.

During the study period, 67% of the 372 children who are active drugs are in the 600 mg of groundnut protein – two things, 4% of the 124 children, without a single allergic symptom, are just a plusbo group. More than half of the drug group will consume 1000 ml of fodder protein-a third of four kernels – compared to 2% in the platon group. When allergies had symptoms, ALS01 children had more critical responses than the pupils of the PlayBox group.

The differences between the two groups of adults are very important, and the drugs are most effective for children.

While the results were offered, some people still suffer from severe allergic reaction in this study. About 6% of the affected people experienced "critical or severe adverse events" during their studies. It is 2% in the Plas group. These reactions did not cause damage or casualties. 43 cases were withdrawn from the drug group and three playbox groups. From classical allergic reactions to gastrointestinal symptoms.

Next, the FDA will review the safety and efficiency of data and decide whether to accept drugs. The FDA will allow the Aimmune approval to be approved by the end of 2019, the company said.

If that goal is damaged, the AR101 may be the first authorized treatment of allergies in the market. Last year, Australian researchers say that integrated immunotherapy and probiotics allow some of the allergic reptiles for young children to take root roots, but such treatment is not available to consumers.

Write Jamie Ducharme at [email protected]

Source link